Direct genetic analysis of single disseminated cancer cells for prediction of outcome and therapy selection in esophageal cancer.
Standard
Direct genetic analysis of single disseminated cancer cells for prediction of outcome and therapy selection in esophageal cancer. / Stoecklein, Nikolas H; Hosch, Stefan B; Bezler, Martin; Stern, Franziska; Hartmann, Claudia H; Vay, Christian; Siegmund, Annika; Scheunemann, Peter; Schurr, Paulus; Knoefel, Wolfram T; Verde Pablo, E; Reichelt, Uta; Erbersdobler, Andreas; Grau, Roger; Ullrich, Axel; Izbicki, Jakob R.; Klein, Christoph A.
in: CANCER CELL, Jahrgang 13, Nr. 5, 5, 2008, S. 441-453.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Direct genetic analysis of single disseminated cancer cells for prediction of outcome and therapy selection in esophageal cancer.
AU - Stoecklein, Nikolas H
AU - Hosch, Stefan B
AU - Bezler, Martin
AU - Stern, Franziska
AU - Hartmann, Claudia H
AU - Vay, Christian
AU - Siegmund, Annika
AU - Scheunemann, Peter
AU - Schurr, Paulus
AU - Knoefel, Wolfram T
AU - Verde Pablo, E
AU - Reichelt, Uta
AU - Erbersdobler, Andreas
AU - Grau, Roger
AU - Ullrich, Axel
AU - Izbicki, Jakob R.
AU - Klein, Christoph A
PY - 2008
Y1 - 2008
N2 - The increasing use of primary tumors as surrogate markers for prognosis and therapeutic decisions neglects evolutionary aspects of cancer progression. To address this problem, we studied the precursor cells of metastases directly for the identification of prognostic and therapeutic markers and prospectively analyzed single disseminated cancer cells from lymph nodes and bone marrow of 107 consecutive esophageal cancer patients. Whole-genome screening revealed that primary tumors and lymphatically and hematogenously disseminated cancer cells diverged for most genetic aberrations. However, we identified chromosome 17q12-21, the region comprising HER2, as the most frequent gain in disseminated tumor cells that were isolated from both ectopic sites. Survival analysis demonstrated that HER2 gain in a single disseminated tumor cell but not in primary tumors conferred high risk for early death.
AB - The increasing use of primary tumors as surrogate markers for prognosis and therapeutic decisions neglects evolutionary aspects of cancer progression. To address this problem, we studied the precursor cells of metastases directly for the identification of prognostic and therapeutic markers and prospectively analyzed single disseminated cancer cells from lymph nodes and bone marrow of 107 consecutive esophageal cancer patients. Whole-genome screening revealed that primary tumors and lymphatically and hematogenously disseminated cancer cells diverged for most genetic aberrations. However, we identified chromosome 17q12-21, the region comprising HER2, as the most frequent gain in disseminated tumor cells that were isolated from both ectopic sites. Survival analysis demonstrated that HER2 gain in a single disseminated tumor cell but not in primary tumors conferred high risk for early death.
M3 - SCORING: Zeitschriftenaufsatz
VL - 13
SP - 441
EP - 453
JO - CANCER CELL
JF - CANCER CELL
SN - 1535-6108
IS - 5
M1 - 5
ER -